Results 11 to 20 of about 172,233 (314)
Antiviral anticoagulation [PDF]
Research and Practice in Thrombosis and Haemostasis, 2020 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel envelope virus that causes coronavirus disease 2019 (COVID-19). Hallmarks of COVID-19 are a puzzling form of thrombophilia that has elevated D-dimer but only modest effects on other parameters of coagulopathy.
Pryzdial, Edward L. G. +3 more
openaire +3 more sources
Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves. insights from the nationwide plectrum study [PDF]
, 2021 Vitamin K antagonists are indicated for the thromboprophylaxis in patients with mechanical prosthetic heart valves (MPHV). However, it is unclear whether some differences between acenocoumarol and warfarin in terms of anticoagulation quality do exist. We
Poli D. +8 more
core +1 more source
Anticoagulants and Osteoporosis [PDF]
International Journal of Molecular Sciences, 2019 Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong (heparins) to suggest caution in their use in subjects at risk of osteoporosis.
Signorelli S. S. +5 more
openaire +2 more sources
A retrospective comparative study of three data modelling techniques in anticoagulation therapy. [PDF]
, 2008 Three types of data modelling technique are applied retrospectively to individual patients’ anticoagulation therapy data to predict their future levels of anticoagulation.
Angelov, Plamen +5 more
core +1 more source
, 2022 Thrombotic diseases are some of the leading causes of death in the world. Anticoagulation is a mainstay approach for the prophylaxis and treatment of thrombotic diseases. This book includes six chapters regarding the mechanisms of anticoagulation and its
core +1 more source
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
Research and Practice in Thrombosis and Haemostasis, 2021 Background Coagulopathy has been reported in severely ill patients with coronavirus disease 2019 (COVID‐19). It is unclear whether outpatients with COVID‐19 who are treated with vitamin K antagonists (VKAs) have unstable anticoagulation.
Eleonora Camilleri +6 more
doaj +1 more source
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
Research and Practice in Thrombosis and Haemostasis, 2022 Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria. The presence of LA is detected (or excluded) by laboratory testing, with the activated partial thromboplastin time and dilute Russell's viper venom time ...
Emmanuel J. Favaloro, Leonardo Pasalic
openaire +3 more sources
British Medical Bulletin, 2000 Anticoagulation is a treatment with significant and life threatening complications requiring that the balance of risk and benefit be individually assessed in each patient. The risks are greater in the elderly and those with hypertension, falls and gastrointestinal disease.
openaire +2 more sources
Medicina, 2021 Background and Objectives: Although the need for anticoagulation to prevent thromboembolism is increasing and non-vitamin K antagonist oral anticoagulants (NOACs) have been tried, there is still controversy about the efficacy of anticoagulation in ...
Mi-Ryung Kim +8 more
doaj +1 more source
Open Heart, 2023 Objective There is a substantial incidence of stroke in patients with atrial fibrillation (AF) not receiving anticoagulation. The reasons for not receiving anticoagulation are generally attributed to clinician’s choice, however, a proportion of AF ...
Ajay K Kakkar +14 more
doaj +1 more source